1-Methyl-4,5,6,7-tetrahydrobenzotriazol | 58265-27-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并三唑类
• 英文名称: 1-Methyl-4,5,6,7-tetrahydrobenzotriazol
• 英文别名: 1-methyl-4,5,6,7-tetrahydro-1H-benzo[1,2,3]triazole；1-Methyl-4,5,6,7-tetrahydrobenzotriazole
• CAS: 58265-27-3
• 化学式: C₇H₁₁N₃
• 分子量: 137.184
• InChiKey: LVQLNOWMMHLQIA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  30.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  3-methyl-3,4,5,6,7,7a-hexahydro-benzo[1,2,3]triazol-3a-ol 、 盐酸 以25%的产率得到
  参考文献：
  名称：

  OLSEN C. E., ACTA CHEM. SCAND. , 1975, B29, NO 9, 953-962

  摘要：

  DOI：

文献信息

• [EN] BICYCLIC COMPOUNDS FOR USE AS RIP1 KINASE INHIBITORS<br/>[FR] COMPOSÉS BICYCLIQUES DESTINÉS À ÊTRE UTILISÉS EN TANT QU'INHIBITEURS DE LA KINASE RIP1
  申请人：HOFFMANN LA ROCHE

  公开号：WO2019072942A1

  公开（公告）日：2019-04-18

  The invention provides novel compounds having the general formula (I) or pharmaceutically acceptable salts thereof, wherein RA, RB1, RB2, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds, and methods of using the compounds as RIP1 kinase inhibitors.

  这项发明提供了具有通式（I）或其药用可接受盐的新化合物，其中RA、RB1、RB2、A环和B环如本文所述，包括这些化合物的药物组合物，以及将这些化合物用作RIP1激酶抑制剂的方法。
• SUBSTITUTED OXETANES, METHOD OF MAKING, AND METHOD OF USE THEREOF
  申请人：Howell Amy R.

  公开号：US20080139566A1

  公开（公告）日：2008-06-12

  Oxetane-containing nucleosides, particularly non-reducing psiconucleoside oxetanes are described herein. Therapeutic application of these oxetane compounds toward the treatment of nucleoside analog related disorders such as disorders involving cellular proliferation and infection are also described.

  本文描述了含有氧杂环丙烷的核苷，特别是非还原的偏心核苷氧杂环丙烷。还描述了这些氧杂环丙烷化合物在治疗与核苷类似物相关的疾病，例如涉及细胞增殖和感染的疾病的治疗应用。
• Inhibitors of the menin-MLL interaction
  申请人：VITAE PHARMACEUTICALS, LLC

  公开号：US10683302B2

  公开（公告）日：2020-06-16

  The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.

  本发明涉及 menin 与 MLL 和 MLL 融合蛋白相互作用的抑制剂、含有这些抑制剂的药物组合物，以及它们在治疗癌症和由 menin-MLL 相互作用介导的其他疾病中的用途。
• INHIBITORS OF THE MENIN-MLL INTERACTION
  申请人：VITAE PHARMACEUTICALS, INC.

  公开号：US20190144459A1

  公开（公告）日：2019-05-16

  The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.
• US7351827B2
  申请人：——

  公开号：US7351827B2

  公开（公告）日：2008-04-01